Idéal Investisseur Galteron Galteron
Français English
CAC 40 : Market open
8 306,28 pts
-0.55%


Last updated : 17/11/2026 - 09h35
🏠 Home   ➤    Stock news

MaaT Pharma: €10.1 Million in Cash, Financing Secured Until End of 2026

As of September 30, 2026, MaaT Pharma had €10.1 million in cash and cash equivalents, compared with €24.9 million as of December 31, 2025. Including the 2025 research tax credit of €3.7 million received in October, the Lyon-based biotech estimates it can fund its operations until the end of December 2026.

Its revenue amounted to €0.5 million in the third quarter and €1.6 million over the first nine months. This amount comes from the compassionate access program, whose operations were transferred to Clinigen in January 2026, which changes the way sales are recorded.


MaaT Pharma: €10.1 Million in Cash, Financing Secured Until End of 2026

Declining Cash and Financing Secured Until End of December

The cash position published as of September 30 does not take into account the research tax credit, which was collected after the close of the quarter. It is by adding this amount that the company sets its financing horizon at the end of December 2026, based on its current operating plan and financial commitments.

Looking ahead, MaaT Pharma states that it "continues to actively explore financing opportunities with investors as well as strategic partnerships." The end-2026 deadline had already been highlighted by the company in October 2026, in its communication regarding candidate MaaT034.

The Clinigen Contract Brings Published Sales to €1.6 Million Over Nine Months

Since January 2026, MaaT Pharma no longer delivers directly to hospitals: it sells its product to Clinigen, which then supplies healthcare institutions in Europe. The company's revenue therefore now relies on the financial terms of the license agreement, namely a transfer price and royalties.

This transition explains the gap between the net revenue reported over nine months and the €3.3 million it would have reached under the former model. This level is stable compared with the €3.4 million recorded over the first nine months of 2025: the decline in published revenue is due to the change in distribution model, while the underlying business remains stable.

Recent Clinical and Regulatory Data Ahead of the ASH Congress

The publication follows two announcements regarding the clinical portfolio. On October 19, 2026, following a meeting held prior to filing a clinical trial application, the company indicated that the U.S. health authority did not anticipate additional non-clinical safety studies for MaaT034 in solid tumors.

On November 6, 2026, MaaT Pharma commented on the first data from a Phase 2a trial sponsored by AP-HP in metastatic melanoma, in which MaaT013 was well tolerated, with no gain in response. The company specified that these results will inform its development strategy.

By the end of the year, it plans to take part in several conferences, including the SFGM-TC congress in Marseille and the 68th annual ASH meeting in New Orleans, from December 12 to 15, 2026.

The underlying commercial activity thus remains at last year's level, while the continuation of operations beyond the end of December 2026 falls within the financing and partnership discussions the company has initiated.

Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning ✓ Euronext data ✓ AI-powered analysis


Sector Pharmacie et biotechnologies › Biotechnologies


Context

Period
  • Period: 9M 2026
Key reported figures
  • Revenue: 1,6 millions d'euros
  • Quarterly revenue: 1,6 millions d'euros
  • Revenue growth: -52,9 %
Risks mentioned
  • Transition of EAP program to Clinigen resulted in significant revenue decline from EUR 3.3M to EUR 1.6M 9M result
  • Financial terms of licensing agreement with Clinigen are restrictive on net revenue reporting
  • Company has limited cash resources through end of Q4 2026
Opportunities identified
  • EAP program transition to Clinigen enables wider hospital distribution in Europe
  • Licensing agreement with Clinigen provides recurring, predictable revenue stream
  • Pre-transition revenue basis of EUR 3.3M demonstrates underlying demand for the product

The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.

Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.

Advertisement
Every morning
Technical market signals,
before the opening bell.
CAC 40 · SBF 120 · Signals · Analysts
🤖
Today's edition — pre-market
CAC 40
7 702
-0,87%
SBF 120
5 827
-0,87%
📈 Bullish signals
+5,2%
+1,8%
+0,9%
📉 Bearish signals
-14%
-5,7%
🔄 Analyst opinions
▲ 35 €
▼ 80 €
Sign up to see everything →
Before 9 AM every morning
Euronext data
AI-powered analysis





BOURSE · Chaque matin
La synthèse bourse,
avant l'ouverture.
Notre moteur analyse chaque nuit le CAC 40 et le SBF 120. Ce qui mérite attention remonte directement dans votre boîte mail. Gratuit.
✓ Avant 9h00 ✓ 1000+ inscrits ✓ 100% gratuit
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours sur les valeurs Euronext, chaque matin avant 9h.
tendance · 6 séances
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours